Company intelligence / Profile preview

Aranex

Ownership: Private
Employees: ~2
Development stage: Other

Overview

Aranex Biotech was an early-stage agricultural biotechnology company focused on developing hypoallergenic peanuts to address the global epidemic of peanut allergies. Founded in 2015 by Chloe Gui and Terry Huang, the company utilized CRISPR-Cas9 gene-editing technology to precisely target and turn off the genes encoding major peanut allergens, such as Ara h 1, Ara h 2, and Ara h 3. By eliminating these immunogenic proteins at the genomic level, Aranex aimed to produce a safe, allergen-free peanut crop that could prevent life-threatening anaphylactic reactions. The company participated in the IndieBio EU synthetic biology accelerator in Cork, Ireland, but was ultimately deadpooled and went out of business around 2019.

Therapeutic areas: Immunology
Modalities: CRISPR-based therapy
Industry: Agriculture & AgTech

Partnerships

ICRISAT

Beyond the preview

Go deeper on Aranex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aranex.